All News

AAO-HNS Continues Advocacy on Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis (2/5/2020)

AAO-HNS Continues Advocacy on Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis (2/5/2020)

On February 5, the AAO-HNS sent comments to Blue Cross Blue Shield’s Federal Employee Program (BCBS FEP) opposing their medical policy designating balloon ostial dilation (BSOD) as experimental/investigational. The comment letter highlights the AAO-HNS Position Statement and Clinical Consensus Statement on BSOD, as well as provides extensive literature support demonstrating the procedure is consistent with the standard of care.

Save the Date for the AAO-HNSF 2024 Annual Meeting & OTO EXPOLearn More